Cranbury Pharmaceuticals Receives US FDA Approval for First Generic Version of Emflaza® Oral Suspension (Deflazacort) for Duchenne Muscular Dystrophy

Cranbury Pharmaceuticals, a wholly-owned subsidiary of Tris Pharma, announced the US FDA approved the Abbreviated New Drug Application for the first generic version of Emflaza® oral suspension (deflazacort) for the treatment of Duchenne muscular dystrophy. The generic deflazacort oral suspension is now available to patients in the United States.